Switch theme
Sign up to access all valuation multiples
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
1986
484
LTM Revenue $128M
LTM EBITDA $19.4M
$375M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lifecore Biomedical has a last 12-month revenue (LTM) of $128M and a last 12-month EBITDA of $19.4M.
In the most recent fiscal year, Lifecore Biomedical achieved revenue of $128M and an EBITDA of $36.5M.
Lifecore Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lifecore Biomedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $128M | XXX | $128M | XXX | XXX | XXX |
| Gross Profit | $39.9M | XXX | $41.9M | XXX | XXX | XXX |
| Gross Margin | 31% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $19.4M | XXX | $36.5M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 28% | XXX | XXX | XXX |
| EBIT | -$7.2M | XXX | -$7.2M | XXX | XXX | XXX |
| EBIT Margin | -6% | XXX | -6% | XXX | XXX | XXX |
| Net Profit | -$43.7M | XXX | $12.0M | XXX | XXX | XXX |
| Net Margin | -34% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $113M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lifecore Biomedical's stock price is $7.
Lifecore Biomedical has current market cap of $250M, and EV of $375M.
See Lifecore Biomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $375M | $250M | XXX | XXX | XXX | XXX | $-1.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lifecore Biomedical has market cap of $250M and EV of $375M.
Lifecore Biomedical's trades at 2.9x EV/Revenue multiple, and 14.1x EV/EBITDA.
Equity research analysts estimate Lifecore Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lifecore Biomedical has a P/E ratio of -5.7x.
See valuation multiples for Lifecore Biomedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $250M | XXX | $250M | XXX | XXX | XXX |
| EV (current) | $375M | XXX | $375M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 19.3x | XXX | 14.1x | XXX | XXX | XXX |
| EV/EBIT | -51.9x | XXX | -52.0x | XXX | XXX | XXX |
| EV/Gross Profit | 9.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.7x | XXX | -12.2x | XXX | XXX | XXX |
| EV/FCF | -67.0x | XXX | -34.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLifecore Biomedical's last 12 month revenue growth is 3%
Lifecore Biomedical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Lifecore Biomedical's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lifecore Biomedical's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lifecore Biomedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 64% | XXX | XXX | XXX |
| Rule of 40 | 9% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lifecore Biomedical acquired XXX companies to date.
Last acquisition by Lifecore Biomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Lifecore Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lifecore Biomedical founded? | Lifecore Biomedical was founded in 1986. |
| Where is Lifecore Biomedical headquartered? | Lifecore Biomedical is headquartered in United States of America. |
| How many employees does Lifecore Biomedical have? | As of today, Lifecore Biomedical has 484 employees. |
| Who is the CEO of Lifecore Biomedical? | Lifecore Biomedical's CEO is Mr. Paul Josephs. |
| Is Lifecore Biomedical publicy listed? | Yes, Lifecore Biomedical is a public company listed on NAS. |
| What is the stock symbol of Lifecore Biomedical? | Lifecore Biomedical trades under LFCR ticker. |
| When did Lifecore Biomedical go public? | Lifecore Biomedical went public in 1996. |
| Who are competitors of Lifecore Biomedical? | Similar companies to Lifecore Biomedical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Lifecore Biomedical? | Lifecore Biomedical's current market cap is $250M |
| What is the current revenue of Lifecore Biomedical? | Lifecore Biomedical's last 12 months revenue is $128M. |
| What is the current revenue growth of Lifecore Biomedical? | Lifecore Biomedical revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Lifecore Biomedical? | Current revenue multiple of Lifecore Biomedical is 2.9x. |
| Is Lifecore Biomedical profitable? | Yes, Lifecore Biomedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lifecore Biomedical? | Lifecore Biomedical's last 12 months EBITDA is $19.4M. |
| What is Lifecore Biomedical's EBITDA margin? | Lifecore Biomedical's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Lifecore Biomedical? | Current EBITDA multiple of Lifecore Biomedical is 19.3x. |
| What is the current FCF of Lifecore Biomedical? | Lifecore Biomedical's last 12 months FCF is -$5.6M. |
| What is Lifecore Biomedical's FCF margin? | Lifecore Biomedical's last 12 months FCF margin is -4%. |
| What is the current EV/FCF multiple of Lifecore Biomedical? | Current FCF multiple of Lifecore Biomedical is -67.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
